Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
about
Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expressionEpithelial cell dissemination and readhesion: analysis of factors contributing to metastasis formation in breast cancerTherapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in JapanPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerPredictive and prognostic molecular markers for cancer medicineSupervised risk predictor of breast cancer based on intrinsic subtypesProspective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapyA proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responsesGene expression profiling of breast cancer.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer.Deconstructing the molecular portraits of breast cancer.Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma.Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteriaLocal recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapyThe role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior.An interactive tool for individualized estimation of conditional survival in rectal cancer.A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer.Nomogram for predicting breast conservation after neoadjuvant chemotherapy.Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator.The Computerized Table Setting Test for Detecting Unilateral Neglect.Letrozole in the neoadjuvant setting: the P024 trial.A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.Clinical nomogram to predict bone-only metastasis in patients with early breast carcinomaClinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancerHigh rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.Antibacterial-coated suture in reducing surgical site infection in breast surgery: a prospective study.A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerClinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomasA Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patientsGenomic grade index is associated with response to chemotherapy in patients with breast cancer.Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
P2860
Q24321199-A31E2521-3C65-438F-B624-991B4460CB77Q24606925-EF586FB8-9639-48B3-86BC-2D0ABFDF6F48Q24633384-607895C7-C5DB-4651-890A-BBBE911B0A28Q28240692-511EA6DC-8D04-4703-B455-80900CC3B951Q28743108-4B88387C-D577-4AD8-98DE-5F1BBA03ED7CQ29617404-F7B07CD4-FAE2-4ADF-9B92-90544668B4F2Q30433483-AA813081-AF2B-4504-B6DD-D12B228E7105Q30434260-561154F9-BB77-47C0-BBA3-A22E9FDA103EQ33267359-91E047F3-60BB-4E43-90A6-8CAC809E78C2Q33325635-29E2CF0C-31C1-4C0B-90E0-17E6F434465DQ33555497-70512241-9451-4361-8931-F473A4070513Q33698446-1FF6691C-948C-40ED-BBF1-1FC482ABE9B3Q33864348-A2E2AA5A-99B3-42CF-B333-85DBE1A940DCQ34154147-0BF9B79F-5972-4251-BE14-6CC3B1711526Q34174451-AF8E8AE0-EF87-40C4-A510-0270DB3C1D63Q34275072-8BB894AA-C510-4F15-A71F-F95A21D87E5AQ34300562-C4315BB7-F9AF-4B74-8915-4E1917984284Q35000348-CCEF6925-DE5E-4D79-9C15-C2944C8170FFQ35000874-287E9B7C-5F0E-4B67-8AE0-E474021C101CQ35034623-B41E34C5-0DFC-433D-A337-F48AA26232DBQ35075617-361AE761-54D5-4787-8122-F9FFEF180D3FQ35122705-7D3D2E14-BB0E-4C54-AF12-D3960AC27D6EQ35165402-E40750A2-A5FF-4324-A9F7-F1BEDD177D24Q35198325-BBDD6CE6-361D-4FD9-BC56-7C27838154C8Q35429810-7B57EBDF-F6C6-468B-A4BB-4E6CEB2996E6Q35609692-3581C49C-ED2C-4F45-AB3E-4FFFF52F1EC8Q35803615-DA2BF7EB-D415-4E91-8E05-2F8DECC4508CQ35895131-328DBC46-E465-4FB2-92A3-5BAC635AD17DQ36026549-C7451653-8C54-43C1-BE99-A17D588A33CDQ36096451-DEE71F38-AAAE-4915-AD40-6279D3F4B124Q36295018-A822C804-01A5-41F2-8D8F-7FD4E9D62841Q36458727-1F54C410-17E6-4F57-BB76-B873EAF965C6Q36484592-07F424F1-39BD-4C3B-8744-D5147958DAE0Q36505782-8E4D5FA8-D061-43A3-8685-F6CABB50C6EBQ36593931-A5B88030-63BA-4223-AF35-D58DB9E99C68Q36594068-CEEEDC80-D5EC-4E84-A046-6C8DFD17C3C3Q37220398-849545E6-2EF6-4620-9389-94D74CF9A686Q37244377-A5ED8C8C-428D-4847-B4C8-424CE18A18F5Q37278382-348813EB-C8E5-45C5-94B8-F70D733B5F4DQ37347500-1B4D75AF-21CC-4121-B91B-4F932C484073
P2860
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Nomograms to predict pathologi ...... hemotherapy for breast cancer.
@en
type
label
Nomograms to predict pathologi ...... hemotherapy for breast cancer.
@en
prefLabel
Nomograms to predict pathologi ...... hemotherapy for breast cancer.
@en
P2093
P50
P356
P1476
Nomograms to predict pathologi ...... hemotherapy for breast cancer.
@en
P2093
Aman U Buzdar
Ana M Gonzalez-Angulo
David Atallah
Donald A Berry
Fabrice Andre
Gabriel N Hortobagyi
Jean-Remi Garbay
Kenneth R Hess
Lajos Pusztai
Marc Spielmann
P304
P356
10.1200/JCO.2005.01.2898
P407
P577
2005-11-01T00:00:00Z